JP2017510602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510602A5 JP2017510602A5 JP2016561629A JP2016561629A JP2017510602A5 JP 2017510602 A5 JP2017510602 A5 JP 2017510602A5 JP 2016561629 A JP2016561629 A JP 2016561629A JP 2016561629 A JP2016561629 A JP 2016561629A JP 2017510602 A5 JP2017510602 A5 JP 2017510602A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- siponimod
- weight
- form according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims description 38
- KIHYPELVXPAIDH-HNSNBQBZSA-N 1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-HNSNBQBZSA-N 0.000 claims description 21
- 229950005693 siponimod Drugs 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000000314 lubricant Substances 0.000 claims description 10
- 239000002274 desiccant Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000005192 partition Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940114926 stearate Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977806P | 2014-04-10 | 2014-04-10 | |
| US61/977,806 | 2014-04-10 | ||
| PCT/IB2015/052552 WO2015155711A1 (en) | 2014-04-10 | 2015-04-08 | Immunosuppressant formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009871A Division JP2020097591A (ja) | 2014-04-10 | 2020-01-24 | 免疫抑制製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510602A JP2017510602A (ja) | 2017-04-13 |
| JP2017510602A5 true JP2017510602A5 (cg-RX-API-DMAC7.html) | 2018-05-17 |
| JP6679495B2 JP6679495B2 (ja) | 2020-04-15 |
Family
ID=53525213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561629A Active JP6679495B2 (ja) | 2014-04-10 | 2015-04-08 | 免疫抑制製剤 |
| JP2020009871A Withdrawn JP2020097591A (ja) | 2014-04-10 | 2020-01-24 | 免疫抑制製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009871A Withdrawn JP2020097591A (ja) | 2014-04-10 | 2020-01-24 | 免疫抑制製剤 |
Country Status (23)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6111202B2 (ja) | 2011-01-07 | 2017-04-05 | ノバルティス アーゲー | 免疫抑制製剤 |
| PT3129006T (pt) * | 2014-04-10 | 2021-04-09 | Novartis Ag | Formulação imunossupressora |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| CN111107837A (zh) * | 2017-09-27 | 2020-05-05 | 诺华股份有限公司 | 包含西普尼莫德的肠胃外制剂 |
| EP3687531A1 (en) | 2017-09-29 | 2020-08-05 | Novartis AG | Dosing regimen of siponimod |
| CN111107845A (zh) | 2017-09-29 | 2020-05-05 | 诺华股份有限公司 | 西尼莫德的给药方案 |
| US11673860B2 (en) | 2018-01-22 | 2023-06-13 | Teva Pharmaceuticals International Gmbh | Crystalline siponimod fumaric acid and polymorphs thereof |
| CN109908095A (zh) * | 2019-04-08 | 2019-06-21 | 肇庆学院 | 一种西尼莫德片剂及制备方法 |
| WO2021214717A1 (en) | 2020-04-23 | 2021-10-28 | Novartis Ag | Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome |
| CN113633632A (zh) * | 2021-09-09 | 2021-11-12 | 暨南大学附属第一医院（广州华侨医院） | siponimod在制备抗肿瘤转移药物中的应用 |
| EP4633611A1 (en) | 2022-12-12 | 2025-10-22 | Synthon B.V. | Pharmaceutical composition of siponimod |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3120833A1 (en) * | 2007-10-12 | 2017-01-25 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| GB2473399B (en) | 2008-07-16 | 2012-06-27 | Nec Corp | Method for reporting information about result of Iu-UP protocol negotiation protocol conversion method,communication network system |
| RU2011129230A (ru) | 2008-12-18 | 2013-01-27 | Новартис Аг | Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты |
| SI2379497T1 (sl) | 2008-12-18 | 2013-12-31 | Novartis Ag | Hemifumaratna sol 1-(4-(1-(4-ciklohaksil-3-trifluorometil-benziloksiimino)-etil)-2-etil- benzil)azetidin-3-karboksilne kisline |
| NZ593427A (en) * | 2008-12-22 | 2013-11-29 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| CN101480374A (zh) * | 2009-01-20 | 2009-07-15 | 苏州中化药品工业有限公司 | 一种稳定的固体药物组合物 |
| JP6111202B2 (ja) * | 2011-01-07 | 2017-04-05 | ノバルティス アーゲー | 免疫抑制製剤 |
| WO2012095853A1 (en) * | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| PT3129006T (pt) * | 2014-04-10 | 2021-04-09 | Novartis Ag | Formulação imunossupressora |
-
2015
- 2015-04-08 PT PT157357336T patent/PT3129006T/pt unknown
- 2015-04-08 MX MX2016013236A patent/MX2016013236A/es unknown
- 2015-04-08 CA CA2942236A patent/CA2942236C/en active Active
- 2015-04-08 JP JP2016561629A patent/JP6679495B2/ja active Active
- 2015-04-08 SG SG11201607354PA patent/SG11201607354PA/en unknown
- 2015-04-08 EP EP15735733.6A patent/EP3129006B1/en active Active
- 2015-04-08 SI SI201531566T patent/SI3129006T1/sl unknown
- 2015-04-08 PE PE2016001740A patent/PE20161385A1/es not_active Application Discontinuation
- 2015-04-08 EA EA201692043A patent/EA201692043A1/ru unknown
- 2015-04-08 HU HUE15735733A patent/HUE054245T2/hu unknown
- 2015-04-08 DK DK15735733.6T patent/DK3129006T3/da active
- 2015-04-08 US US15/300,968 patent/US20170027906A1/en not_active Abandoned
- 2015-04-08 PL PL15735733T patent/PL3129006T3/pl unknown
- 2015-04-08 KR KR1020167027528A patent/KR102466348B1/ko active Active
- 2015-04-08 CN CN201580018811.7A patent/CN106163502B/zh active Active
- 2015-04-08 ES ES15735733T patent/ES2865451T3/es active Active
- 2015-04-08 AU AU2015246038A patent/AU2015246038C1/en active Active
- 2015-04-08 WO PCT/IB2015/052552 patent/WO2015155711A1/en not_active Ceased
- 2015-04-09 TW TW104111464A patent/TW201622707A/zh unknown
- 2015-04-10 AR ARP150101084A patent/AR100002A1/es unknown
-
2016
- 2016-09-01 IL IL247599A patent/IL247599B/en active IP Right Grant
- 2016-09-20 PH PH12016501841A patent/PH12016501841A1/en unknown
- 2016-10-07 CL CL2016002560A patent/CL2016002560A1/es unknown
-
2018
- 2018-03-20 US US15/926,699 patent/US20180207128A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,696 patent/US20190328705A1/en not_active Abandoned
-
2020
- 2020-01-24 JP JP2020009871A patent/JP2020097591A/ja not_active Withdrawn
-
2021
- 2021-02-04 US US17/167,635 patent/US20210161860A1/en not_active Abandoned
-
2024
- 2024-03-14 US US18/605,259 patent/US20250073203A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510602A5 (cg-RX-API-DMAC7.html) | ||
| WO2015155711A4 (en) | Immunosuppressant formulation | |
| ZA202303338B (en) | Orodispersible dosage unit containing an estetrol component | |
| JP2018534348A5 (cg-RX-API-DMAC7.html) | ||
| JP2017226708A5 (cg-RX-API-DMAC7.html) | ||
| PH12017502325A1 (en) | Orodispersible dosage unit containing an estetrol component | |
| JP2012193216A5 (cg-RX-API-DMAC7.html) | ||
| FI3182975T3 (fi) | Rukaparibin suuren annosvahvuuden tabletteja | |
| NZ612686A (en) | Sublingual films | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| EA201170954A1 (ru) | Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения | |
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2015150303A (ru) | Композиция, содержащая гидрокортизон | |
| JP6630343B2 (ja) | 抗酸化剤を含有する固形製剤 | |
| JP2017520619A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510787A5 (cg-RX-API-DMAC7.html) | ||
| JP2016535762A5 (cg-RX-API-DMAC7.html) | ||
| SI2805714T1 (en) | A stable pharmaceutical composition comprising amorphous rosuvastatin calcium | |
| RU2017136567A (ru) | Фармацевтическая композиция с замедленным высвобождением, содержащая ривастигмин | |
| RU2013107724A (ru) | Фармацевтические композиции монтелукаста и левоцетиризина | |
| EA202091455A1 (ru) | Стабилизированный фармацевтический состав, содержащий эверолимус | |
| RU2019103647A (ru) | Композиция с задержанным высвобождением, содержащая микронизированный толкапон | |
| JP2016102101A (ja) | オルメサルタンメドキソミル含有錠剤 | |
| NZ710967A (en) | Pharmaceutical compositions containing dexketoprofen and tramadol |